Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 26, 2011 - Issue 5
Submit an article Journal homepage
782
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Quinoxalin-2-carboxamides: synthesis and pharmacological evaluation as serotonin type-3 (5-HT3) receptor antagonists

Radhakrishnan MaheshAssociate Professor and Group Leader, Pharmacy Group, FD-III, Birla Institute of Technology & Science, Pilani, Rajasthan, India
,
Thangaraj DevadossResearch Scholar, Pharmacy Group, FD-III, Birla Institute of Technology & Science, Pilani, Rajasthan, IndiaCorrespondence[email protected]
,
Dilip Kumar PandeyVeterinary in charge, Central Animal Facility, FD-III, Birla Institute of Technology & Science, Pilani, Rajasthan, India
&
Shushil Kumar YadavVeterinary in charge, Central Animal Facility, FD-III, Birla Institute of Technology & Science, Pilani, Rajasthan, India
Pages 610-615 | Received 12 Feb 2010, Accepted 20 Nov 2010, Published online: 11 Jan 2011

References

  • Tralongo P, Dimari A, Conti G, Aiello R, Mauceri G. Central nervous system side-effects of 5-HT3-receptor antagonists in elderly cancer patients treated with chemotherapy. Ann Oncol 2004;15:987–988.
  • Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end–patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203–208.
  • Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482–2494.
  • Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007;61:162–175.
  • Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293:34–44.
  • Cubeddu LX. Mechanisms by which cancer chemotherapeutic drugs induce emesis. Semin Oncol 1992;19:2–13.
  • Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12:1143–1150.
  • Ohtaka H, Fujita T., In: Jucker E, ed. Progress in Drug Research, Chap. 4, Vol. 41. Switzerland: Birkhauser Verlag Basel, 1993:338.
  • Mahesh R, Perumal RV, Pandi PV. Pharmacophore based synthesis of 3-chloroquinoxaline-2-carboxamides as serotonin3 (5-HT3) receptor antagonist. Biol Pharm Bull 2004;27:1403–1405.
  • Clark RD, Miller AB, Berger J, Repke DB, Weinhardt KK, Kowalczyk BA, Eglen RM, Bonhaus DW, Lee CH, Michel AD. 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists. J Med Chem 1993;36:2645–2657.
  • Ohta M, Suzuki T, Koide T, Matsuhisa A, Furuya T, Miyata K, Yanagisawa I. Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives. Chem Pharm Bull 1996;44:991–999.
  • Venkatesha Perumal R, Mahesh R. Synthesis and biological evaluation of a novel structural type of serotonin 5-HT3 receptor antagonists. Bioorg Med Chem Lett 2006;16:2769–2772.
  • Hibert MF, Hoffmann R, Miller RC, Carr AA. Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site. J Med Chem 1990;33:1594–1600.
  • Paton WD, Zar MA. The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol (Lond) 1968;194:13–33.
  • MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol 1978;30:312–313.
  • Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997;23:3–25.
  • Harms AE. An efficient synthesis of 2-quinoxalinecarboxylic acid. Org Process Res Dev 2004;8:666–669.
  • Mahesh R, Perumal RV, Pandi PV. Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorg Med Chem Lett 2004;14:5179–5181.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.